Drugplain

Olanzapine 10 mg/2mL

Olanzapine · INJECTION, POWDER, FOR SOLUTION · XGen Pharmaceuticals DJB, Inc.

10 Recalls on Record
Plain English

Olanzapine is a injection, powder, for solution containing olanzapine at 10 mg/2mL, taken intramuscular. Manufactured by XGen Pharmaceuticals DJB, Inc..

Key Facts

Brand Name
Olanzapine
Generic Name
Olanzapine
NDC Code (Product)
39822-1800
Manufacturer
XGen Pharmaceuticals DJB, Inc.
Strength
10 mg/2mL
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAMUSCULAR
Marketing Status
Application #
ANDA211072
Drug Class
Atypical Antipsychotic [EPC]
Marketing Start
08/28/2025

Recall History

10 Recalls on Record
Class III03/22/2017

Sun Pharmaceutical Industries, Inc.

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

TerminatedVoluntary: Firm initiated
Class III05/26/2020

Aurobindo Pharma USA Inc.

Failed Impurities/ Degradation Specifications

TerminatedVoluntary: Firm initiated
Class II02/16/2022

Macleods Pharma Usa Inc

cGmp Deviations

TerminatedVoluntary: Firm initiated
Class III04/07/2015

Apotex Inc.

Subpotent drug

TerminatedVoluntary: Firm initiated
Class II06/29/2021

Eli Lilly & Company

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

TerminatedVoluntary: Firm initiated
Class III03/22/2017

Sun Pharmaceutical Industries, Inc.

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling:Label Mixup; OLANZAPINE, Tablet 7.5 mg may be potentially mislabeled as NORTRIPTYLINE HCL, Capsule, 75 mg, NDC 00093081301, Pedigree: AD21790_73, EXP: 5/1/2014.

TerminatedVoluntary: Firm initiated
Class II07/22/2013

Torrent Pharma Inc

Defective Container; This action is being taken as a precautionary measure due to the product being re-packaged in the U.S. using a filler material that (removes or blocks) less moisture than what is approved in the application.

TerminatedVoluntary: Firm initiated
Class III10/13/2016

Dr. Reddy's Laboratories, Inc.

Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

TerminatedVoluntary: Firm initiated
Class III04/18/2014

Apotex Corp.

Subpotent Drug: Out of specification (OOS) results at the 9 month temperature point.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective5,720 reports
off label use4,104 reports
toxicity to various agents3,765 reports
drug interaction3,264 reports
weight increased2,741 reports
somnolence2,643 reports
nausea2,640 reports
condition aggravated2,288 reports
vomiting2,269 reports
suicide attempt2,252 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drug

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Schizophrenia in adults ( 2.1 ) Oral: Start at 5 mg to 10 mg once daily; Target: 10 mg/day within several days Schizophrenia in adolescents ( 2.1 ) Oral: Start at 2.5 mg to 5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) in adults ( 2.2 ) Oral: Start at 10 mg or 15 mg once daily Bipolar I Disorder (manic or mixed episodes) in adolescents ( 2.2 ) Oral: Start at 2.5 mg to 5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults ( 2.2 ) Oral: Start at 10 mg once daily Depressive Episodes associated with Bipolar I Disorder in adults ( 2.5 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Depressive Episodes associated with Bipolar I Disorder in children and adolescents ( 2.5 ) Oral in combination with fluoxetine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily Treatment Resistant Depression in adults ( 2.6 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Lower starting dose recommended in debilitated or pharmacodynamically sensitive p

Contraindications

4 CONTRAINDICATIONS None with olanzapine monotherapy. When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax. For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products. None with olanzapine monotherapy.( 4 ) When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax ® . ( 4 ) When using olanzapine in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products. ( 4 )

Drug Interactions

7 DRUG INTERACTIONS The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. Diazepam: May potentiate orthostatic hypotension. ( 7.1 , 7.2 ) Alcohol: May potentiate orthostatic hypotension. ( 7.1 ) Carbamazepine: Increased clearance of olanzapine. ( 7.1 ) Fluvoxamine: May increase olanzapine levels. ( 7.1 ) Olanzapine and Fluoxetine in Combination: Also refer to the Drug Interactions section of the package insert for Symbyax. ( 7.1 ) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs and alcohol. ( 7.2 ) Antihypertensive Agents: Enhanced antihypertensive effect. ( 7.2 ) Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists. ( 7.2 ) Other Concomitant Drug Therapy: When using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products. ( 7.2 ) 7.1 Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine [see Drug Interactions ( 7.2 )] . Cimetidine and Antacids — Sin

Adverse Reactions

6 ADVERSE REACTIONS When using olanzapine and fluoxetine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax. Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Oral Olanzapine Monotherapy: Schizophrenia (Adults) – postural hypotension, constipation, weight gain, dizziness, personality disorder, akathisia ( 6.1 ) Schizophrenia (Adolescents) – sedation, weight increased, headache, increased appetite, dizziness, abdominal pain, pain in extremity, fatigue, dry mouth ( 6.1 ) Manic or Mixed Episodes, Bipolar I Disorder (Adults) – asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor ( 6.1 ) Manic or Mixed Episodes, Bipolar I Disorder (Adolescents) – sedation, weight increased, increased appetite, headache, fatigue, dizziness, dry mouth, abdominal pain, pain in extremity ( 6.1 ) Combination of Olanzapine and Lithium or Valproate: Manic or Mixed Episodes, Bipolar I Disorder (Adults) – dry mouth, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia ( 6.1 ) Olanzapine and Fluoxetine in Combination: Also ref

Frequently Asked Questions

What is Olanzapine used for?

Olanzapine contains Olanzapine. It is a injection, powder, for solution taken intramuscular. Consult your doctor for specific uses.

Is Olanzapine a controlled substance?

Olanzapine is not classified as a controlled substance by the DEA.

What is the generic name for Olanzapine?

The generic name for Olanzapine is Olanzapine. There are 3 other brand versions of Olanzapine.

What is the NDC code for Olanzapine 10 mg/2mL?

The NDC (National Drug Code) for Olanzapine 10 mg/2mL is 39822-1800, listed by XGen Pharmaceuticals DJB, Inc..